The objective of the present invention is to provide a method for producing a halogenated carbonyl safely and efficiently. The method for producing a halogenated carbonyl according to the present invention is characterized in comprising the step of applying ultrasound to a composition containing a C.sub.1-4 halogenated hydrocarbon having one or more halogeno groups selected from the group consisting of chloro, bromo and iodo in the presence of oxygen to decompose the C.sub.1-4 halogenated hydrocarbon.

A method of forming dialkyl carbonate is provided, which includes introducing carbon dioxide into a catalyst to form dialkyl carbonate, wherein the catalyst is formed by activating a catalyst precursor using alcohol, wherein alcohol is R.sup.3—OH, and R.sup.3 is C.sub.1-12 alkyl group or C.sub.5-12 aryl or heteroaryl group. The catalyst precursor is formed by reacting Sn(R.sub.1).sub.2(L).sub.2 and Ti(OR.sup.2).sub.4, and Sn(R.sup.1).sub.2(L).sub.2 and Ti(OR.sup.2).sub.4 have a molar ratio of 1:2 to 2:1. R.sup.1 is C.sub.1-10 alkyl group, R.sup.2 is H or C.sub.1-12 alkyl group, and L is O—(C═O)—R.sup.5, and R.sup.5 is C.sub.1-12 alkyl group. The dialkyl carbonate is

##STR00001##

A method of forming dialkyl carbonate is provided, which includes introducing carbon dioxide into a catalyst to form dialkyl carbonate, wherein the catalyst is formed by activating a catalyst precursor using alcohol, wherein alcohol is R.sup.3—OH, and R.sup.3 is C.sub.1-12 alkyl group or C.sub.5-12 aryl or heteroaryl group. The catalyst precursor is formed by reacting Sn(R.sub.1).sub.2(L).sub.2 and Ti(OR.sup.2).sub.4, and Sn(R.sup.1).sub.2(L).sub.2 and Ti(OR.sup.2).sub.4 have a molar ratio of 1:2 to 2:1. R.sup.1 is C.sub.1-10 alkyl group, R.sup.2 is H or C.sub.1-12 alkyl group, and L is O—(C═O)—R.sup.5, and R.sup.5 is C.sub.1-12 alkyl group. The dialkyl carbonate is

##STR00001##

A radiation-sensitive resin composition includes: a first polymer including a structural unit including an acid-labile group; a second polymer including a structural unit represented by formula (1); and a radiation-sensitive acid generator. In the formula (1), A represents an oxygen atom or a sulfur atom; a sum of m and n is 2 or 3, wherein m is 1 or 2, and n is 1 or 2; X represents a single bond or a divalent organic group having 1 to 20 carbon atoms; and R.sup.1 represents a monovalent organic group including a fluorine atom.

##STR00001##

A radiation-sensitive resin composition includes: a first polymer including a structural unit including an acid-labile group; a second polymer including a structural unit represented by formula (1); and a radiation-sensitive acid generator. In the formula (1), A represents an oxygen atom or a sulfur atom; a sum of m and n is 2 or 3, wherein m is 1 or 2, and n is 1 or 2; X represents a single bond or a divalent organic group having 1 to 20 carbon atoms; and R.sup.1 represents a monovalent organic group including a fluorine atom.

##STR00001##

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides radiolabeled compounds of the formula: (I) and (II), as well as precursor compounds of the formula: (VII) wherein the variables are defined herein. The present disclosure also provides radiopharmaceutical compositions comprising the radiolabeled compounds disclosed herein as well as precursor compositions comprising the precursor compounds disclosed herein. The present disclosure further provides methods of imaging using the radiolabeled compounds and/or radiopharmaceutical compositions of the present disclosure as well as kits for the preparation of the radiolabeled compounds and radiopharmaceutical compositions disclosed herein.

##STR00001##

The present application discloses, in part, isolated, stable and biologically active menaquinol derivatives and their methods of use for the treatment of various diseases.

A method of forming dialkyl carbonate is provided, which includes introducing carbon dioxide into a catalyst to form dialkyl carbonate, wherein the catalyst is formed by activating a catalyst precursor using alcohol, wherein alcohol is R.sup.3—OH, and R.sup.3 is C.sub.1-12 alkyl group or C.sub.5-12 aryl or heteroaryl group. The catalyst precursor is formed by reacting Sn(R.sub.1).sub.2(L).sub.2 and Ti(OR.sup.2).sub.4, and Sn(R.sup.1).sub.2(L).sub.2 and Ti(OR.sup.2).sub.4 have a molar ratio of 1:2 to 2:1. R.sup.1 is C.sub.1-10 alkyl group, R.sup.2 is H or C.sub.1-12 alkyl group, and L is O—(C═O)—R.sup.5, and R.sup.5 is C.sub.1-12 alkyl group. The dialkyl carbonate is ##STR00001##